Differentiated thyroid carcinoma in the elderly: influence of age on disease-free and overall survival

Purpose We investigated whether age at diagnosis of differentiated thyroid carcinoma (DTC) may be a risk factor for structural disease and mortality after primary treatment in aging patients. Methods A multicenter, retrospective analysis including patients older than 60 years at DCT diagnosis was de...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine 2022-06, Vol.77 (1), p.121-133
Main Authors: Díez, Juan J., Anda, Emma, Alcazar, Victoria, Isidro, María L., Familiar, Cristina, Paja, Miguel, Rojas Marcos, Patricia, Pérez-Corral, Begoña, Navarro, Elena, Romero-Lluch, Ana R., Oleaga, Amelia, Pamplona, María J., Fernández-García, José C., Megía, Ana, Manjón, Laura, Sánchez-Ragnarsson, Cecilia, Iglesias, Pedro, Sastre, Julia
Format: Article
Language:English
Subjects:
Age
Aging
Diabetes
Diagnosis
Endocrinology
Geriatrics
Humanities and Social Sciences
Internal Medicine
Medicine
Medicine & Public Health
multidisciplinary
Original Article
Papillary thyroid cancer
Patients
Risk factors
Science
Survival analysis
Thyroid cancer
Thyroid carcinoma
Thyroiditis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose We investigated whether age at diagnosis of differentiated thyroid carcinoma (DTC) may be a risk factor for structural disease and mortality after primary treatment in aging patients. Methods A multicenter, retrospective analysis including patients older than 60 years at DCT diagnosis was designed. All subjects were treated by surgery with or without radioiodine adjuvant therapy and had a minimum follow-up of one year. We compared elderly patients (group 1, 60–74 years) with very old patients (group 2, ≥75 years). Results The study involved 1668 patients (74.3% women, median age 67 years, 87.6% papillary thyroid cancer, 73.3% treated with radioiodine), including 1397 in group 1 and 271 in group 2. Patients in group 2 had larger tumor size (1.8 [0.8–3.0] vs 1.5 [0.7–2.8] cm; P  = 0.005), higher proportions of tumors with vascular invasion (23.8 vs 16.4%; P  = 0.006), and lower proportion of lymphocytic thyroiditis (18.6 vs 24.9%; P  = 0.013) than subjects in group 1. Kaplan–Meier survival analysis showed that patients in group 2 had significantly lower structural disease-free survival (DFS) and overall survival (OS) than patients in group 1 ( P  = 0.035 and
ISSN:1559-0100
1355-008X
1559-0100
DOI:10.1007/s12020-022-03059-y